Biohaven Pharmaceutical Holding Stock Number Of Shares Shorted
| BHVN Stock | USD 14.71 0.39 2.58% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Biohaven Pharmaceutical's long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Biohaven Pharmaceutical Holding Company Number Of Shares Shorted Analysis
Biohaven Pharmaceutical's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Biohaven Pharmaceutical Number Of Shares Shorted | 13.48 M |
Most of Biohaven Pharmaceutical's fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biohaven Pharmaceutical Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Biohaven Pharmaceutical Holding has 13.48 M of outstending shares currently sold short by investors. This is 321.48% higher than that of the Biotechnology sector and 164.54% higher than that of the Health Care industry. The number of shares shorted for all United States stocks is 186.57% lower than that of the firm.
Biohaven Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biohaven Pharmaceutical's direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biohaven Pharmaceutical could also be used in its relative valuation, which is a method of valuing Biohaven Pharmaceutical by comparing valuation metrics of similar companies.Biohaven Pharmaceutical is currently under evaluation in number of shares shorted category among its peers.
Biohaven Fundamentals
| Return On Equity | -3.17 | ||||
| Return On Asset | -1.3 | ||||
| Current Valuation | 1.25 B | ||||
| Shares Outstanding | 102.11 M | ||||
| Shares Owned By Insiders | 11.96 % | ||||
| Shares Owned By Institutions | 90.68 % | ||||
| Number Of Shares Shorted | 13.48 M | ||||
| Price To Earning | (4.25) X | ||||
| Price To Book | 5.94 X | ||||
| EBITDA | (841.76 M) | ||||
| Net Income | (846.42 M) | ||||
| Cash And Equivalents | 23.21 M | ||||
| Cash Per Share | 8.48 X | ||||
| Total Debt | 36.58 M | ||||
| Debt To Equity | 0.22 % | ||||
| Current Ratio | 0.71 X | ||||
| Book Value Per Share | 2.54 X | ||||
| Cash Flow From Operations | (582.45 M) | ||||
| Short Ratio | 7.32 X | ||||
| Earnings Per Share | (9.25) X | ||||
| Target Price | 54.21 | ||||
| Number Of Employees | 256 | ||||
| Beta | 3.5 | ||||
| Market Capitalization | 1.54 B | ||||
| Total Asset | 615.11 M | ||||
| Retained Earnings | (1.35 B) | ||||
| Working Capital | 384.25 M | ||||
| Current Asset | 32.52 M | ||||
| Current Liabilities | 3.61 M | ||||
| Net Asset | 615.11 M |
About Biohaven Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biohaven Pharmaceutical Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biohaven Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biohaven Pharmaceutical Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Biohaven Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biohaven Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biohaven Pharmaceutical Holding Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biohaven Pharmaceutical Holding Stock: Check out Biohaven Pharmaceutical Piotroski F Score and Biohaven Pharmaceutical Altman Z Score analysis. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.